Dogwood Therapeutics, Inc. 8-K

What Happened Dogwood Therapeutics, Inc. (DWTX) filed a Form 8-K on March 26, 2026 (Item 7.01) to disclose that it posted a shareholder letter on its website providing a corporate update. The shareholder letter is furnished with the filing as Exhibit 99.1. The report was signed by Angela Walsh, Chief Financial Officer, Corporate Secretary and Treasurer.

Key Details

• Filing date: March 26, 2026 (Form 8-K, Reg FD disclosure — Item 7.01).
• Exhibit: Shareholder letter dated March 26, 2026 furnished as Exhibit 99.1.
• Authorized signatory: Angela Walsh, CFO, Corporate Secretary and Treasurer.
• The filing relates to a corporate update; it does not announce quarterly earnings, revenue figures, executive changes, or other Item 2.02/5.02 disclosures.

Why It Matters This 8-K notifies investors that Dogwood has provided a direct update to shareholders and furnished that communication to the SEC. Retail investors should review the posted shareholder letter (Exhibit 99.1) for any material updates or guidance; absence of separate Item 2.02 (earnings) or Item 5.02 (executive changes) means the filing itself does not contain financial results or management change announcements.